Opens in a new tab

Edwards Lifesciences v Meril Lifesciences (CFI, 18 September 2024)

Date18 September 2024
CourtCFI
DivisionNordic Baltic Regional Division
Type of actionApplication RoP262.1 (b)
Registry referenceApp_33316/2024 · ORD_36322/2024
PartiesKIPA AB

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By a procedural order delivered on 18 September 2024 (UPC_CFI_8/2023, ACT_459769/2023, ORD_36465/2024), the Nordic-Baltic Regional Division (S. Johansson, presiding, K. Härmand, judge-rapporteur, R. Lopes, E. Papa) refused a request for access to all written pleadings and evidence in the action brought by Edwards Lifesciences Corporation against Meril Lifesciences PVT Limited, Meril GmbH, Smis International OÜ and Sormedica UAB for infringement of EP 2 628 464, and in the counterclaims. A single order disposes of the requests filed in the action and in the counterclaims (Nos 33316/2024 and 33491/2024 to 33494/2024). The applicant, whose name is redacted, described itself as a board member and investor in a cardiac implant technology company. Leave to appeal was granted.

Question

Can a member of the public relying on a competitor’s interest in the patent’s validity obtain access, under Rule 262.1(b), to the pleadings of pending proceedings?

Decision

The division accepted that the public has a general interest in access to written pleadings, which are in principle public subject to confidentiality (Art. 45 and 52 UPCA, Art. 47 of the Charter, Regulation No 1049/2001). The interest relied on was, however, very general, and the patent specification is already public. At this stage, protecting the integrity of the pending proceedings prevails. That interest usually lasts until the end of the proceedings, after which access may be more appropriate. The applicant’s precise field of activity mattered little. Costs were awarded against the applicant, and leave to appeal was granted because clarifying the law is of general interest.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 45 and 52
Rules of Procedure
Rule 262.1(b)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
La demande d'accès est rejetée : l'intérêt invoqué est trop général et l'intégrité de la procédure en cours prévaut jusqu'à la fin de l'instance, les frais sont mis à la charge du demandeur et l'appel est autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 628 464Mentioned in the analysis (role not qualified)
Also mentioned in 2 other decision(s): Edwards Lifesciences v Meril Lifesciences (CFI, 21 July 2025) · Edwards Lifesciences v Meril Lifesciences (CFI, 16 August 2024)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.